ST
ICPT

Smithfield Trust’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Smithfield Trust’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-28
Closed -$1K – 1170
2020
Q2 		$1K Buy
+28
New +$2.16K ﹤0.01% 1030

Other funds holding ICPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return

Smithfield Trust's ICPT Position: Q3 2020 in Review

Smithfield Trust sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q3 2020, closing a stake of 28 shares — an estimated $1K sold.

Smithfield Trust first reported a position in ICPT in Q2 2020 and held it in 1 quarter. The position peaked at $1K in Q2 2020. 177 funds tracked by Wall St. Rank hold ICPT as of Q3 2020.

  • Smithfield Trust reported no remaining Intercept Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
  • Smithfield Trust sold 28 Intercept Pharmaceuticals, Inc. shares in Q3 2020, an estimated $1K.
  • Smithfield Trust first reported a position in Intercept Pharmaceuticals, Inc. in Q2 2020 and held it in 1 quarter.
  • Smithfield Trust's Intercept Pharmaceuticals, Inc. position peaked at $1K in Q2 2020.
  • 177 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q3 2020.

Based on Smithfield Trust's 13F filing for Q3 2020, filed 16 Nov 2020.